Find information on thousands of medical conditions and prescription drugs.

Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema, thrombocytopenia (low platelet counts), immune deficiency, and bloody diarrhea (due to the low platelet counts). It is also sometimes called the eczema-thrombocytopenia-immunodeficiency syndrome in keeping with Aldrich's original description in 1954. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
Panniculitis
Waardenburg syndrome
Wagner's disease
WAGR syndrome
Waldenstrom...
Wallerian degeneration
Warkany syndrome
Warts
Waterhouse-Friderichsen...
Watermelon stomach
Wegener's granulomatosis
Weissenbacher Zweymuller...
Werdnig-Hoffmann disease
Werner's syndrome
Whipple disease
Whooping cough
Willebrand disease
Willebrand disease, acquired
Williams syndrome
Wilms tumor-aniridia...
Wilms' tumor
Wilson's disease
Wiskott-Aldrich syndrome
Wolf-Hirschhorn syndrome
Wolff-Parkinson-White...
Wolfram syndrome
Wolman disease
Wooly hair syndrome
Worster-Drought syndrome
Writer's cramp
X
Y
Z
Medicines

Signs and symptoms

WAS generally becomes symptomatic in children. Due to its mode of inheritance, the overwhelming majority are male. It is characterised by bruising caused by thrombocytopenia (low platelet counts), small platelet size on blood film, eczema, recurrent infections, and a propensity for autoimmune disorders and malignancies (mainly lymphoma and leukemia).

In Wiskott-Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts. Also, patients develop a type of itchy rash called eczema. Autoimmune disorders are also found in patients with WAS.

Diagnosis

The diagnosis is made on the basis of clinical parameters, the blood film and low immunoglobulin levels. Skin immunologic testing (allergy testing) may reveal hyposensitivity. It must be remembered that not all patients will have a family history, since they may be the first to harbor the gene mutation. Often, leukemia may initially be suspected on the basis of the low platelets and the infections, and bone marrow biopsy may be performed. Decreased levels of Wiskott-Aldrich syndrome protein and/or confirmation of a causative mutation provides the most definitive diagnosis.

Read more at Wikipedia.org


[List your site here Free!]


Stability of JC Virus Coding Sequences in a Case of Progressive Multifocal Leukoencephalopathy in Which the Viral Control Region Was Rearranged Markedly
From Archives of Pathology & Laboratory Medicine, 3/1/04 by Zheng, Huai-Ying

Context.-It is generally accepted that JC virus variants in the brains of patients with progressive multifocal leukoencephalopathy are generated from archetypal strains through sequence rearrangement (deletion and duplication, or deletion alone) in the control region. This change is thought to occur during persistence of JC virus in patients.

Objective.-The present study was performed to ascertain whether amino acid substitution in the viral proteins is involved in the generation and propagation of JCV variants with rearranged control regions.

Design.-Many complete JC DNA clones were established from brain tissues (cerebellum, occipital lobe, and brainstem) autopsied in a case of progressive multifocal leukoencephalopathy in which multiple distinct control sequences were detected. Control and coding sequences were determined and compared among the JC DNA clones.

Results.-Twenty-eight control-region and 20 coding sequences of JC virus were compared. Five rearranged control sequences were detected, but they could be classified into 3 groups that shared common structural features. Viral coding sequences were identical among clones with different control regions and among clones derived from different brain regions.

Conclusion.-In the present case, nucleotide substitution in the viral coding regions (and resultant amino acid change in the viral proteins) was involved neither in the genesis of rearranged JC virus variants nor in the proliferation of demyelinated lesions in the brain.

(Arch Pathol Lab Med. 2004;128:275-278)

Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system that affects individuals with decreased immunocompetence.1 The causative agent is the human polyomavirus JC virus (JCV), first isolated in 1971 from the brain of a PML patient.2 Although PML was once a rare disease, it is now a common opportunistic infection in patients with acquired immunodeficiency syndrome.3

Most individuals are asymptomatically infected with JCV during childhood.4,5 The infecting JCV reaches the kidney, probably through viremia, and persists there throughout life.6,7 In adults, the renal JCV replicates and excretes progeny in urine.8-11 Renal JCV DNA carries the archetype control region (archetype CR)/ whereas JCV DNA in the brain of PML patients contains various CRs (PML-type CRs) that harbor deletions and duplications, or deletions alone, in reference to the archetype.12-15

To explain the correlation between archetype and PML-type JCVs, Yogo and Sugimoto15 proposed the archetype concept, which is formulated as follows: (1) JCVs with the archetype CR are circulating in the human population; (2) the archetype CR is highly conserved, in marked contrast to the hypervariable CRs (PML-type CRs) of JCVs in the brain of PML patients; (3) each PML-type CR is produced from the archetype by deletion and duplication, or by deletion alone; (4) the shift of the CR from archetype to PML type occurs during persistence in the host; and (5) PML-type JCVs never return to the human population.

The archetype concept assumes that no amino acid change in the viral proteins is involved in the generation of PML-type JCV To examine this assumption, we studied a PML case in which multiple, distinct, PML-type JCVs were detected in autopsied brain tissues."' We established and sequenced many complete JCV DNA clones. Viral coding sequences were identical among clones with different control regions and among clones derived from different brain regions. We concluded that nucleotide substitution (and resultant amino acid change) was involved neither in the genesis of rearranged JCVs nor in the proliferation of demyelinated lesions in the brain.

MATERIALS AND METHODS

A detailed case report was published previously.16 In brief, a 14-year-old boy with Wiskott-Aldrich syndrome suffered from progressive impairment of ocular movement and annrthria 6 months after allogenic bone marrow transplantation. T2-weighted magnetic resonance imaging showed high-signal areas in the right occipital lobe, cerebellum, and pons. JC viral DNA was detected in the cerebrospinal fluid by nested polymerase chain reaction. Several therapeutic approaches were not effective, and the patient died 8 months after bone marrow transplantation.

DNA was previously extracted from autopsied brain tissues (cerebellum, occipital lobe, and brainstem).16 From these DNA samples, entire JCV DNA sequences were cloned into pUC19 at the unique BamHI site, ns described elsewhere.17 The resultant recombinant plasmids containing complete JCV DNA sequences were prepared using a QIAGEN Plasmid Midi kit (QIAGEN GmbH, Hilden, Germany). Purified plasmids were sequenced as described by Sugimoto et al.18 The CR sequences were aligned by eye in reference to the archetype sequence,12 while entire DNA sequences, excluding the CR sequences, were aligned with the CLUSTAL W program (ftp://ftp-igbmc.u-strasbg.fr).19

RESULTS

Control Region Sequences

We established 14 clones from the cerebellum, 7 from occipital lobe, and 8 from brainstem (29 total). We first determined the CR sequences of these clones. We identified 5 rearranged CR sequences, designated CRs I to V. These sequences are diagrammatically represented in the Figure in reference to the archetype CR at the top. Deletions in rearranged sequences I through V are shown as gaps, with duplications depicted by parallel lines. Control regions I, II, and IV corresponded to TK-Ia, -Ic, and -Id, respectively, previously identified by polymerase chain reaction from the same brain tissue DNA.16 Control regions III and V were not detected in the previous study.16

The structural features of the 5 CR sequences are summarized as follows: (1) CR I had only deletions, whereas the others (II to V) had both deletions and duplications. (2) Control regions II and III had 2 common deletions, spanning nucleotides (nt) 37 to 60 and nt 201 to 247. However, duplications in CRs II and III were unique, and CR III had a small deletion (nt 138-139) not present in CR II. These features suggest that the same intermediate carrying only the common deletions generated CRs II and III by different subsequent changes. (3) Control regions IV and V shared the same deletion (nt 63-85) and the same breakpoints (nt 41 and 110). However, these CRs also had a unique deletion (IV) and unique duplications (IV and V). A common intermediate probably generated IV and V, but it was not readily inferred how this intermediate produced CRs IV and V. all in all, it was concluded that at least 3 independent CR rearrangements occurred in a JCV strain (or strains) in the present PML case.

In the present case of PML, we previously amplified various rearranged CRs of JCV in the brain using polymerase chain reaction and found that each rearranged CR showed a unique distribution pattern in the brain.1'1 These distribution patterns were confirmed in the present study, for which many complete JCV DNA clones were analyzed (see the Table). Thus, CR 1 (TK-Ia) was widespread in the brain, with the highest incidence in the cerebellum; CR II (TK-1c) mainly occurred in the occipital lobe; and CR IV (TK-1d) mainly occurred in the brainstem. In addition, CR III, which was first detected in the present study but was structurally related to CR II (see above), was detected only in the occipital lobe, where CR II was mainly detected.

Coding Sequences

JC virus DNA clones were classified into groups according to origin and CR sequences (Table). We determined the complete coding sequences of representative or all clones belonging to these groups (Table). A single complete coding sequence of JCV was mainly detected in the brain in the current case, but a minor complete coding sequence was detected in the 3 clones with CR IV. These minor clones carried T at a position (nt 824) within the VP2 (a minor capsid protein) gene, whereas the major clones carried C at this position. A clone with CR V (CR structurally related to CR IV) carried C, rather than T, at nt 824. The C/T nucleotide change at position 824 caused an amino acid difference of alanine/valine (a change between amino acids with similar properties).

The result regarding the complete coding sequences described above had 2 implications. First, the complete coding sequence was identical regardless of the structures of CRs. The CR sequences were classified into 3 groups with distinct rearrangements. Thus, the identity of the complete coding sequence among clones with distinctly rearranged CRs suggested that in the present PML case, JCV DNA sequences with distinctly rearranged CRs were generated from the same archetype strain. second, the complete coding sequence was identical among clones that carried the same CR, even if they were derived from different brain regions. For example, the same complete coding sequence (ie, the sequences harboring C at nt 824) was detected in all clones with CR I derived from all 3 brain regions. Likewise, this sequence was detected in all clones with CR II derived from 2 brain regions (cerebellum and occipital lobe).

COMMENT

It is now generally accepted that JCV variants in the brains of PML patients (PML-type JCVs) are generated from archetype strains through sequence rearrangement (deletion and duplication, or deletion alone) in the CR.12-14,20,21 Yogo and Sugimoto15 developed this view into the archetype concept. This concept assumes that no significant amino acid change in the viral proteins is involved in the generation of PML-type JCVs. We used a PML case in which multiple distinct PML-type JCVs were detected in the brain to examine this assumption.16 We established and sequenced many complete JCV DNA clones from autopsied brain tissues and compared CR and coding sequences among the JCV DNA clones obtained. Five CR sequences were detected in total, but they could be classified into 3 groups that we believe evolved independently from the archetype. The same complete coding sequence was detected in most clones with various CRs, excluding CR IV. Although we did not analyze the archetype strain that would have generated the various PML-type JCVs, it can be assumed that no common mutation occurred during the genesis of PML-type JCVs.22 Therefore, the detection of the same complete coding sequence in most JCV DNA clones, regardless of the structure of the CR, suggested that the detected complete coding sequence originally existed in the hypothetical archetype JCV and had been conserved during the generation of various PMLtype JCVs.

In JCV isolates with CR IV, we detected a single nucleotide change in the VPl (a minor capsid protein) gene. Because this nucleotide substitution caused only a change between amino acids (alanine and valine) with similar properties, the structure and function of VP2 would not have been influenced by this mutation. all in all, we can conclude that at least in the current case, amino acid substitution in the viral proteins played no important role in the genesis of JCVs with various rearranged CRs.

In the present PML case, the same rearranged CRs occurred in multiple brain regions.16 For instance, CR I occurred in 3 regions (cerebellum, occipital lobe, and brainstem), and CR II occurred in 2 regions (cerebellum and occipital lobe). We believe this observation reflects the proliferation of demyelinated lesions in the brain.16 We detected the same complete coding sequence in JCV DNA clones derived from different brain regions. We concluded that nucleotide substitutions and resultant amino acid changes rarely occurred in the proliferating demyelinated lesions in the brain.

JC viruses that persist in renal tissue and that are excreted in the urine carry the archetype CR and represent JCVs circulating in human populations.15 Zheng et al23 recently investigated how frequently renal/urinary JCVs undergo nucleotide substitution in their coding regions. In brief, they established 5 to 9 complete JCV DNA clones (61 in total) from the urine of 11 individuals (parents and children) belonging to 5 families. The complete sequences of these clones were determined and compared in each family. In the viral coding sequences, 1 or a few nucleotide substitutions per individual were detected in 5 individuals, but none were detected in 6 individuals. It is not easy to compare mutation rates in the coding regions between archetype and PML-type JCVs on the basis of the findings in the present and previous study,21 as only a single PML case was analyzed in the present study. Nevertheless, it is likely that mutation in the JCV genome is not very frequent in PML patients, although sequence rearrangements in the CR more frequently occur in immunosuppressed patients than in immunocompetent patients.24

References

1. Walker DL. Progressive mullifocal leukoencephalopathy. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, eds. Demyelinating Diseases. Amsterdam, The Netherlands: Elsevier; 1985:503-524. Handbook of Clinical Neurology, Vol 3147).

2. Padgett BL, Walker DL, ZuRhein CM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal Ic-ucoencephalopathy. Lancet. 1971 ;1 (7712):1257-1260.

3. Berger JR, Kaszovitz B, Post M), Dickinson C. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: a review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107: 78-87.

4. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus: an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis. 1973;127:467-470.

5. Padgett BL, Walker DL. New human papovaviruses. Prog MedVirol. 1976; 22:1-35.

6. Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983;147:676-684.

7. Tominaga T, Yogo Y, Kitamura T, Aso Y. Persistence of archetypal JC virus DNA in normal renal tissue derived from tumor-bearing patients. Virology. 1992; 186:736-741.

8. Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. I Infect Dis. 1990; 161:1128-1133.

9. Kitamura T, Kunitake T, Guo J, Tominaga T, Kawabe K, Yogo Y. Transmission of the human polyomavirus |C virus occurs both within the family and outside the family. J Clin Micmhiol. 1 994;32:2359-2363.

10. Kitamura T, Sugimoto C, Kato A, et al. Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains, J Clin Microbiol. 1997;35:1255-1257.

11. Agostini HT, Ryschkewitsch CF, Stoner GL. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol. 1996;34:159-164.

12. Yogo Y, Kitamura T, Sugimoto C, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol. 1990; 64:3139-3143.

13. Ault GS, Stoner GL. Two major types of JC virus defined in progressive multifocal leukoencephalopathy brain by early and late coding region DNA sequences. J Gen Virol. 1992;73:2669-2678.

14. Agostini HT, Ryschkewitsch CF, Singer EJ, Stoner GL. JC virus regulatory region rearrangements and genotypes in progressive multifocal leukoencephalopathy: two independent aspects of virus variation. J Gen Virol. 1997;78:659-664.

15. Yogo Y, Sugimoto C. The archetype concept and regulatory region rearrangement. In: Khalili K, Stoner CL, eds. Human Polyomaviruses: Molecular and Clinical Perspectives. New York, NY: John Wiley & Sons; 2001:127-148.

16. Yasuda Y, Yabe H, Inoue H, et al. Comparison of PCR-amplified JC virus control region sequences from multiple brain regions in PML. Neurology. 2003; 61:1617-1619.

17. Yogo Y, lida T, Taguchi F, Kitamura T, Aso Y. Typing of human polyomavirus JC virus on the basis of restriction fragment length polymorphisms. J Clin Microhiol. 1991;29:2130-2138.

18. Sugimoto C, Hasegawa M, Kato A, et al. Evolution of human polyomavirus JC: implications for the population history of humans. J MoL Evol. 2002;54:285-297.

19. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.

20. Flaegstad T, Sundstiord A, Arthur RR, Pedersen M, Traavik T, Subramani S. Amplification and sequencing of the control regions of BK and JC virus from human urine by polymerase chain reaction. Virology. 1991;180:553-560.

21. lida T, Kitamura T, Guo J, et al. Origin of JC polyomavirus variants associated with progressive multifocal leukoencephalopathy. Proc Natl Acad Sci US A. 1993;90:5062-5065.

22. Kato A, Sugimoto C, Zheng HY, Kitamura T, Yogo Y. Lack of disease-specific amino acid changes in the viral proteins of JC virus isolates from the brain with progressive multifocal leukoencephalopathy. Arch Virol. 2000;145:2173-21 82.

23. Zheng HY, Kitamura T, Takasaka T, Chen Q, Yogo Y. Unambiguous identification of JC virus strains transmitted from parents to children. Arch Virol. 2004. In press.

24. Kitamura T, Satoh K, Tominaga T, et al. Alteration in the JC polyomavirus genome is enhanced in immunosuppressed renal transplant patients. Virology. 1994;198:341-345.

25. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol. 1984;51:458-469.

Huai-Ying Zheng, PhD; Yukiharu Yasuda, MD; Shunichi Kato, MD; Tadaichi Kitamura, MD; Yoshiaki Yogo, PhD

Accepted for publication November 4, 2003.

From the Department of Urology, The University of Tokyo, Tokyo, Japan (Drs Zheng, Kitamura, and Yogo), and the Department of Pediatrics, Tokai University of School of Medicine, lsehara, Japan (Drs Yasuda and Kato). Dr Yasuda is now with Yasuda Pediatric Clinic, Machida, Japan.

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Yoshiaki Yogo, PhD, Department of Urology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan (e-mail: yogo-tky@umin.ac.jp).

Copyright College of American Pathologists Mar 2004
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Wiskott-Aldrich syndrome
Home Contact Resources Exchange Links ebay